AU2002335843A1 - Use of ace inhibitors for reducing type 2 diabetes in high risk patients - Google Patents

Use of ace inhibitors for reducing type 2 diabetes in high risk patients

Info

Publication number
AU2002335843A1
AU2002335843A1 AU2002335843A AU2002335843A AU2002335843A1 AU 2002335843 A1 AU2002335843 A1 AU 2002335843A1 AU 2002335843 A AU2002335843 A AU 2002335843A AU 2002335843 A AU2002335843 A AU 2002335843A AU 2002335843 A1 AU2002335843 A1 AU 2002335843A1
Authority
AU
Australia
Prior art keywords
diabetes
high risk
ace inhibitors
risk patients
reducing type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002335843A
Inventor
Salim Yusuf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
King Pharmaceuticals Research and Development Inc
Original Assignee
King Pharmaceuticals Research and Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Research and Development Inc filed Critical King Pharmaceuticals Research and Development Inc
Publication of AU2002335843A1 publication Critical patent/AU2002335843A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
AU2002335843A 2001-10-17 2002-10-17 Use of ace inhibitors for reducing type 2 diabetes in high risk patients Abandoned AU2002335843A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34449501P 2001-10-17 2001-10-17
US60/344,495 2001-10-17
PCT/US2002/033213 WO2003032965A2 (en) 2001-10-17 2002-10-17 Use of ace inhibitors for reducing type 2 diabetes in high risk patients

Publications (1)

Publication Number Publication Date
AU2002335843A1 true AU2002335843A1 (en) 2003-04-28

Family

ID=23350759

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002335843A Abandoned AU2002335843A1 (en) 2001-10-17 2002-10-17 Use of ace inhibitors for reducing type 2 diabetes in high risk patients

Country Status (7)

Country Link
EP (1) EP1438043A2 (en)
JP (1) JP2005531492A (en)
AU (1) AU2002335843A1 (en)
CA (1) CA2463682A1 (en)
IL (1) IL161388A0 (en)
MX (1) MXPA04003022A (en)
WO (2) WO2003032965A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2458288A1 (en) * 2003-03-11 2004-09-11 Institut De Cardiologie De Montreal / Montreal Heart Institute Method and compound to reduce the incidence of diabetes in a subject with chronic heart failure
US20050065184A1 (en) * 2003-08-29 2005-03-24 Aaipharma Inc. Method of reducing the risk of oxidative stress
CN101573110A (en) * 2006-08-28 2009-11-04 塞诺菲-安万特德国有限公司 Methods of lowering glucose levels
PT2970123T (en) 2013-03-14 2019-10-28 Cytokinetics Inc Salt of omecamtiv mecarbil and process for preparing salt
RU2652343C2 (en) * 2013-06-26 2018-04-25 Тон-А Ст Ко., Лтд Composition for preventing or treating renal diseases, containing dpp-iv inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0331014A3 (en) * 1988-03-02 1991-10-23 THERA - Patent Verwaltungs-GmbH Use of ace inhibitors in diabetes prophylaxis
DE4308504A1 (en) * 1993-03-18 1994-09-22 Knoll Ag New use of a combination of verapamil and trandolapril
SE9903028D0 (en) * 1999-08-27 1999-08-27 Astra Ab New use
JP4870888B2 (en) * 1999-08-30 2012-02-08 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Use of renin-angiotensin system inhibitors in the prevention of cardiovascular conditions

Also Published As

Publication number Publication date
EP1438043A2 (en) 2004-07-21
CA2463682A1 (en) 2003-04-24
WO2003032963A3 (en) 2003-12-24
WO2003032965A2 (en) 2003-04-24
MXPA04003022A (en) 2004-07-05
WO2003032965A3 (en) 2003-11-27
IL161388A0 (en) 2004-09-27
WO2003032963A2 (en) 2003-04-24
JP2005531492A (en) 2005-10-20

Similar Documents

Publication Publication Date Title
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
AU2002326600A1 (en) Side-exit catheter and method for its use
AUPP609198A0 (en) Use of non-peptidyl compounds for the treatment of insulin related ailments
AU2003223579A1 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
AU2000276362A1 (en) Composition for the treatment of diabetes
AU2003279442A1 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
AU2003201071A1 (en) Stable pharmaceutical compositions comprising ace inhibitor(s)
HUP0301830A3 (en) Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
AU2002335843A1 (en) Use of ace inhibitors for reducing type 2 diabetes in high risk patients
AU2003242755A1 (en) Novel pharmaceutical compositions comprising novel anticholinergic agents and pde-iv inhibitors
AU2002327440A1 (en) Treatment of type i diabetes
AU2003281176A1 (en) Medicinal composition for mitigating blood lipid or lowering blood homocystein
AU7653600A (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
AU2003280393A1 (en) Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors
AU2003240446A1 (en) Use of mob-5 in pain
AU2002342715A1 (en) Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors
AU2003257814A1 (en) Medicinal composition for lowering blood lipid level
AU4650500A (en) Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis
AU2003216954A1 (en) Treatment of dependence and dependence related withdrawal symptoms
AU2002245598A1 (en) Administration of sleep restorative agents
AU2003243998A1 (en) Syringe for containing medical liquid and medical liquid in syringe
AU2002249232A1 (en) Use of $g(g)-gt inhibitors for the treatment of degenerative diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase